Core Viewpoint - Meiya has been subjected to an investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, alongside receiving a warning from the Hubei Securities Regulatory Bureau [1][2]. Group 1: Investigation and Regulatory Actions - Meiya and its actual controller, Chairman Zheng Jiping, received a notice of investigation from the CSRC due to suspected information disclosure violations [1][2]. - The Hubei Securities Regulatory Bureau issued a warning letter to Meiya and related personnel, citing issues such as undisclosed related party transactions and inaccuracies in the 2022 annual report [3]. Group 2: Financial Irregularities - Meiya was found to have engaged in related party transactions without proper review and disclosure, including a transaction of 5.4 million yuan with its indirect controlling shareholder [3]. - The company has been involved in non-operating fund occupation, where funds were transferred to Zheng Jiping's related party, which have since been returned [3]. Group 3: Financial Performance - Meiya is projecting a net loss attributable to shareholders of between 86 million yuan and 44 million yuan for 2024, attributed to decreased revenue from its pharmaceutical segment and increased competition in the apparel market [6]. - The overall gross margin of the company has declined due to these factors, reflecting a challenging market environment [6]. Group 4: Management Changes - Recent personnel changes include the resignation of Zhang Jingya as a supervisor and Zheng Anbo as a non-independent director, both citing personal reasons [6].
美尔雅及公司实控人遭证监会立案 同日还被出具警示函